Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors?
AYA
adolescent
checkpoint inhibitors immunotherapy and AYA patients
fertility
immunotherapy
long-term toxicities
pregnancy
young adults
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
07
2021
accepted:
30
08
2021
entrez:
11
10
2021
pubmed:
12
10
2021
medline:
12
10
2021
Statut:
epublish
Résumé
Immunotherapy has changed the landscape of treatments for advanced disease in multiple neoplasms. More and more patients are long survivors from a metastatic disease. Most recently, the extension of indications and evidence of efficacy in early disease settings, such as the adjuvant and neoadjuvant setting in breast cancer, lung cancer, glioma, and gastric cancer, places more attention on what happens to patients who survive cancer. In particular, we evaluated what happens in young patients, a population in whom some immune-related effects are still poorly described. Immunotherapy is already a reality in early disease settings and the scientific community is lagging in describing what to expect in adolescent and young adult (AYA) patients. For instance, the impact of these therapies on female and male fertility is not clear, similarly to the interaction that may occur between these drugs and pregnancy. This review aims to highlight these little-known topics that are difficult to evaluate in
Identifiants
pubmed: 34631569
doi: 10.3389/fonc.2021.736123
pmc: PMC8495150
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
736123Informations de copyright
Copyright © 2021 Tanda, Croce, Spagnolo, Zullo, Spinaci, Genova and Rossi.
Déclaration de conflit d'intérêts
CG received honoraria from Astra Zeneca, Bristol-Myers-Squibb, Merck-Sharp-Dohme, Roche, and Boehringer-Ingelheim. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Pediatr Hematol Oncol. 2017 Jul;39(5):e263-e266
pubmed: 27841828
J Clin Oncol. 2021 Oct 10;39(29):3293-3305
pubmed: 34197218
Breast Cancer Res Treat. 2008 May;109(1):123-39
pubmed: 17578664
JNCI Cancer Spectr. 2019 Aug 01;3(4):pkz057
pubmed: 32337483
Cancer. 2021 Apr 1;127(7):1021-1028
pubmed: 33259061
Nat Med. 2019 Mar;25(3):477-486
pubmed: 30742122
J Leukoc Biol. 2020 Jan;107(1):119-132
pubmed: 31573727
Am J Dermatopathol. 2005 Aug;27(4):279-85
pubmed: 16121045
Semin Oncol. 2018 Jun;45(3):164-169
pubmed: 30262400
Clin Obstet Gynecol. 2015 Mar;58(1):119-24
pubmed: 25517755
BJOG. 2012 Dec;119(13):1572-82
pubmed: 22947229
Melanoma Res. 2019 Jun;29(3):333-337
pubmed: 30730328
Lancet. 2007 Nov 10;370(9599):1609-21
pubmed: 17993361
Cancer J. 2018 Nov/Dec;24(6):267-274
pubmed: 30480571
Eur J Cancer. 2003 Dec;39(18):2651-61
pubmed: 14642927
Cancers (Basel). 2020 Jul 27;12(8):
pubmed: 32726988
J Exp Med. 2005 Jul 18;202(2):231-7
pubmed: 16027236
Pediatrics. 2005 Mar;115(3):649-54
pubmed: 15741367
Cancer. 2014 Jan 1;120(1):20-5
pubmed: 24347383
JAMA Dermatol. 2018 Mar 1;154(3):361-362
pubmed: 29387875
Int J Environ Res Public Health. 2016 Feb 19;13(2):231
pubmed: 26907308
Cancer. 2015 Jun 15;121(12):2072-7
pubmed: 25737403
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
J Immunother Cancer. 2019 Jul 3;7(1):165
pubmed: 31269983
Am J Reprod Immunol. 2009 Nov;62(5):283-92
pubmed: 19811462
Lancet. 2020 Oct 10;396(10257):1090-1100
pubmed: 32966830
JAMA Oncol. 2017 Sep 1;3(9):1190-1196
pubmed: 28418444
Oncologist. 2020 Apr;25(4):277-278
pubmed: 32091651
J Glob Oncol. 2018 Sep;4:1-3
pubmed: 30241195
Cancer. 2007 Aug 1;110(3):614-24
pubmed: 17577228
Eur J Epidemiol. 2007;22(10):723-35
pubmed: 17828436
J Eur Acad Dermatol Venereol. 2019 Mar;33(3):541-545
pubmed: 30408254
JAMA Dermatol. 2016 Mar;152(3):268-75
pubmed: 26818409
Ann Oncol. 2016 Feb;27(2):214-24
pubmed: 26578728
Ann Oncol. 2015 Sep;26(9):1824-1829
pubmed: 25888611
Breast Cancer Res Treat. 2017 Aug;165(1):1-8
pubmed: 26700035
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
Appl Immunohistochem Mol Morphol. 2014 Jan;22(1):57-64
pubmed: 24471189
Lancet Oncol. 2019 Jul;20(7):948-960
pubmed: 31160251
Crit Rev Oncol Hematol. 2017 May;113:213-234
pubmed: 28427510
Melanoma Res. 2020 Aug;30(4):423-425
pubmed: 32073510
Semin Oncol. 2009 Jun;36(3):237-49
pubmed: 19460581
Ann Lab Med. 2020 Mar;40(2):114-121
pubmed: 31650727
N Engl J Med. 2021 Apr 1;384(13):1191-1203
pubmed: 33789008
Breast Cancer Res Treat. 2012 Aug;135(1):291-9
pubmed: 22833199
J Dtsch Dermatol Ges. 2021 May;19(5):762-765
pubmed: 33768686
BMJ. 2012 Jul 24;345:e4757
pubmed: 22833605
CA Cancer J Clin. 2020 Nov;70(6):443-459
pubmed: 32940362
Eur J Cancer. 2021 May;149:153-164
pubmed: 33865201
Eur J Cancer. 2018 Nov;104:239-242
pubmed: 30454709
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Ann Oncol. 2020 Dec;31(12):1664-1678
pubmed: 32976936
Ann Surg Oncol. 2004 Mar;11(3):247-58
pubmed: 14993019
J Am Acad Dermatol. 2016 Sep;75(3):528-534
pubmed: 27543212
Cancer. 2009 Sep 15;115(18):4176-85
pubmed: 19536874
J Invest Dermatol. 2015 Mar;135(3):816-823
pubmed: 25268584
Clin Cancer Res. 2016 Mar 15;22(6):1364-70
pubmed: 26534966
Birth Defects Res B Dev Reprod Toxicol. 2016 Apr;107(2):108-19
pubmed: 27062127
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
Oncologist. 2019 Nov;24(11):e1148-e1155
pubmed: 31036771
J Clin Oncol. 2019 Nov 1;37(31):2825-2834
pubmed: 31487218
Lancet Child Adolesc Health. 2019 Sep;3(9):646-654
pubmed: 31204309
J Clin Oncol. 2009 Jan 1;27(1):45-51
pubmed: 19029418